Maintain pressure on reforms to protect NHSSorafenib increases life expectancy in liver cancer patients
According to the study of 602 patients with advanced hepatocellular carcinoma, patients treated with the drug lived 44% longer than those who received a placebo.
Median overall survival was 10.7 months in a sorafenib group and 7.9 months in the placebo group.
‘This is the first time that we've had an effective systemic treatment for liver cancer,’ said lead author Josep Llovet, director of research in liver cancer at Mount Sinai School of Medicine in New York.
‘Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful.’
New England Journal of Medicine (2008) 359: 378-390
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.